Sunvozertinib Yields Tolerability, Efficacy in EGFR+ NSCLC
Sunvozertinib shows a similar safety profile to other EGFR tyrosine kinase inhibitors in the treatment of EGFR wild-type non–small cell lung cancer in the WO-KONH6 study.
PRT811 Yields Early Anti-Tumor Activity in Uveal Melanoma/Advanced Glioma
Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.
Encorafenib Combo Yields Promising Activity in BRAF V600E-Mutant mCRC
Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.
Durable Survival Benefit Observed Following HD-ASCT Vs Non-Myeloablative CRT for Primary CNS Lymphoma
Patients with with primary central nervous system lymphoma experienced prolonged progression-free survival and a reduction in risk of death following treatment with high-dose chemotherapy and autologous stem cell transplant compared with non-myeloablative chemoimmunotherapy.
Survival Benefit Observed Following Treatment With Belantamab Mafodotin for Relapsed/Refractory Myeloma
A triple-class exposed population of patients diagnosed with relapsed or refractory multiple myeloma experienced progression-free survival benefit following treatment with belantamab mafodotin with pomalidomide and dexamethasone.
Disease Progression Lessened With Ribociclib Plus Endocrine Therapy in Pre/Perimenopausal HR+/HR– Advanced Breast Cancer
The phase RIGHT Choice trial yield a 46% reduction in disease progression when ribociclib was added to endocrine therapy for patients with pre/perimenopausal hormone-receptor–positive/HER2-negative advanced breast cancer.
Optimal Sequencing of Immunotherapy Followed by BRAK/MEK Inhibitor Identified in BRAF+ Advanced Melanoma
Findings from the phase 3 DREAMseq trial indicated that the best course of treatment for individuals diagnosed with advanced BRAF-mutated melanoma is first-line nivolumab/ipilimumab, with BRAF/MEK inhibitors used in later-line settings.
Significant HRQOL Boost With Larotrectinib Reported in TRK+ Solid Tumors
Benefits of larotrectinib in patients with tumors harboring NTRK fusions have been established, with new data showing health-related quality of life benefits with its use.
CDKN2A/B Enrichment and EGFR Mutations Appear Linked With Brain Metastasis in NSCLC
An analysis presented at 2022 ASCO reveals a potential correlation between CDKN2A/B as well as cell cycle pathway alterations and brain metastases in non–small cell lung cancer.
Larotrectinib Continues to Improve Responses in TRK Fusion+ CNS Tumors
Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.
Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab
Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.
Darolutamide Yields Positive, Long-Lasting Outcomes in nmCRPC With or Without Prior Local Therapy
Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.
Promising Responses Observed With Axi-Cel in High-Risk LBCL
Patients with high-risk large B-cell lymphoma experienced potent, long-term responses following treatment with axicabtagene ciloleucel in the first line.
CoVac-1 Yields Yields Promising Results in Those With Cancer-Related Immunoglobulin Deficiency
The CoVac-1 vaccine appears to reduce COVID-19 symptoms for patients with cancer who have disease- or treatment-related immunoglobulin deficiency.
Various Monoclonal Antibodies Enhance Durvalumab Efficacy in Resectable, Early-Stage NSCLC
Adjuvant durvalumab combined with different monoclonal antibodies led to enriched major pathologic responses in early-stage non–small cell lung cancer.
Response Acheivement With Nivolumab Plus Ipilimumab Combo for Clear Cell RCC Linked With Immune Cell–Related Factirs
Data from the TITAN-RCC trial presented at 2022 ASCO GU showed that certain immune cell–related parameters may be predictive of response to nivolumab/ipilimumab in advanced or metastatic clear cell renal cell carcinoma
Tolerable Safety Profile Seen With Onvansertib Combo in KRAS-Mutant mCRC
Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.
Dose Reduction of Selinexor Combo Demonstrates Efficacy in Multiple Myeloma
A post hoc analysis showed that a dose reduction of selinexor yielded higher safety and efficacy for patients with multiple myeloma.
Selinexor Plus Vd Combo Shows Potential as a Treatment Option for High-Risk Multiple Myeloma
Weekly selinexor combined with bortezomib and dexamethasone appears to be a promising option in patients with high-risk multiple myeloma.
Trastuzumab Deruxtecan Added to Pertuzumab May Improve Efficacy in HER2+ Breast Cancer
The combination of trastuzumab deruxtecan and pertuzumab could improve efficacy over trastuzumab deruxtecan alone for patients with HER2-positive metastatic breast cancer.
Cytoreductive Nephrectomy Plus Active Surveillance Continues to Show Promise in mRCC
A select group of patients with metastatic renal cell carcinoma may benefit from cytoreductive nephrectomy followed by active surveillance as an alternative option to systemic therapy.
CRPC Pretreated With Novel Hormonal, Taxane-Based Therapy Derives Benefit From Darolutamide Maintenance
Results of the phase 2 SAKK 08/16 trial indicate a benefit to switching to darolutamide maintenance following prior therapies for metastatic castration-resistant prostate cancer.
Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer
Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.
Despite Early Termination Due to Low Accrual, alloHCT Plus Reduced Intensity Conditioning Safe in Myeloma
When performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan, alloHCT was safe in patients with high-risk multiple myeloma.
Parsaclisib Plus Ruxolitinib to Treat Myelofibrosis Improves Spleen Size and Symptom Burden
Adding parsaclisib to the ruxolitinib treatment of patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone led to improvements in spleen volume reduction and symptom burden.
Phase 2 ENPAC Trial Shows Feasibility of Enzalutamide Triplet in Endometrioid Endometrial Cancer
The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.
ENGOT-OV16/NOVA Study Results Continue to Support Niraparib Maintenance for Patients With gBRCA+/- Ovarian Cancer
PFS improvement as well as a trend to overall survival prolongation has been demonstrated with niraparib maintenance in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.
ROS1+ Metastatic NSCLC Sees Early Benefit With Repotrectinib
“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” according to Byoung Chul Cho, MD, PhD.
Anlotinib Shows Promise as Therapy for Patients With mCRC and Wild-Type RAS/BRAF
Statistically significant improvements in PFS were seen with the multitarget kinase inhibitor anlotinib in Chinese patients with refractory metastatic colorectal cancer, with OS differences noted in certain subgroups.
Oral Azacitidine Improves, Sustains Health-Related QoL in AML
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.
2 Clarke Drive Cranbury, NJ 08512